Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients

Last updated: May 3, 2024
Sponsor: European Institute of Oncology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Abdominal Cancer

Carcinoid Syndrome And Carcinoid Tumours

Treatment

N/A

Clinical Study ID

NCT06343428
IEO 1519
  • Ages > 18
  • All Genders

Study Summary

The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.

The new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs).

However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histological diagnosis of well-differentiated neuroendocrine tumor G3 performed orreviewed by a NEN-dedicated pathologist. In case of "late-NET G3" (see Patients andMethods), a NEN-dedicated pathologist will perform a pathologic review of the previousNET G1/2, too, unless a NEN-dedicated pathologist has already done and except fordiagnoses performed in a NEN-referral Center.
  • Age > 18 years
  • Signed written informed consent
  • Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) (preferably within 6months). If the tumor contained in FFPE tissue block cannot be provided in total,sections from this block should be provided that are freshly cut. Preferably, 25slides should be provided (minimum of 15 slides). If tumor tissue is not available,patients should be willing to undergone to a new biopsy.
  • late-NET G3 patients that will come to our Institute at the moment of NET G3 diagnosiswill be enrolled only if they performed 68 Gallium-DOTATOC positron emissiontomography (PET)/CT and 18 fluorodeoxyglucose (FDG)-PET/CT for the previous NET G1/2.The previous functional imaging performed during the NET G1/2 history shall beavailable for the review by our specialist in nuclear medicine.

Exclusion

Exclusion Criteria:

  • Diagnosis of well-differentiated NET G1/2 or poorly-differentiated NEC
  • Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) in which a NETG3 as neuroendocrine component
  • Cytological diagnosis of NET G3 or not availability of tumor tissue for pathologicalanalysis
  • Concurrent neoplastic disease (e.g. advanced breast or prostatic cancer in hormonaltreatment, hematologic diseases)

Study Design

Total Participants: 20
Study Start date:
July 19, 2021
Estimated Completion Date:
July 19, 2026

Study Description

High-grade neuroendocrine neoplasms (NENs) represent the poorest prognosis category within NENs. During the years, the prognostic differences among the subgroups led to identify at least two subcategories of high-grade NENs, according the morphologic features of the two subtypes.

Indeed, the 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated NENs that called neuroendocrine tumors (NETs) G3 for pancreatic NENs and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs, allowing to separate NET G3 from the other high-grade, poorly-differentiated, NENs, so called neuroendocrine carcinomas (NECs).

However, since the new-category has been introduced, NET G3 category seemed to be more heterogeneous than presumed. Indeed, clinical, pathological and radiological features seemed to identify different prognostic subcategories of NET G3. We recently performed a retrospective analysis on a small pool of 48 NET G3 patients, correlating the clinical outcomes with these different features. The results of our study seemed to suggest prognostic and predictive factors that deserve to be prospectively explored to better understand this pathology and that might to be part of NET G3 multiparametric classification system. Based on the results of our retrospective analysis, we underlined the importance of a systematic and well-designed collection of high-quality data in order to improve our knowledge on this topic.

Connect with a study center

  • European Institute of Oncology

    Milan, 20141
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.